In This Article:
As the U.S. stock market experiences a rise, driven by investor reactions to recent executive orders and economic policies, attention is drawn to various investment opportunities. Penny stocks, though often seen as relics of past market eras, continue to hold potential for investors seeking affordable growth prospects. These stocks typically represent smaller or newer companies that can offer significant upside when supported by strong financials and robust fundamentals.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Financial Health Rating |
| QuantaSing Group (NasdaqGM:QSG) | $3.08 | $108.36M | ★★★★★★ |
| BAB (OTCPK:BABB) | $0.89 | $6.46M | ★★★★★★ |
| Kiora Pharmaceuticals (NasdaqCM:KPRX) | $3.91 | $11.73M | ★★★★★★ |
| Inter & Co (NasdaqGS:INTR) | $4.73 | $2.08B | ★★★★☆☆ |
| ZTEST Electronics (OTCPK:ZTST.F) | $0.275 | $10.12M | ★★★★★★ |
| Permianville Royalty Trust (NYSE:PVL) | $1.58 | $52.14M | ★★★★★★ |
| Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $67.38M | ★★★★★★ |
| BTCS (NasdaqCM:BTCS) | $3.57 | $61.94M | ★★★★★★ |
| Smith Micro Software (NasdaqCM:SMSI) | $1.13 | $20.04M | ★★★★★☆ |
| CBAK Energy Technology (NasdaqCM:CBAT) | $0.8937 | $80.38M | ★★★★★☆ |
Click here to see the full list of 709 stocks from our US Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Alector
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, with a market cap of $167.46 million.
Operations: Alector generates its revenue primarily from its biotechnology segment, amounting to $61.51 million.
Market Cap: $167.46M
Alector, Inc., a clinical-stage biopharmaceutical company, faces challenges typical of penny stocks. Despite promising collaborations with AbbVie and GSK, its AL002 program for Alzheimer’s disease did not meet primary endpoints in recent trials. The company has a solid cash position of US$457.2 million to support operations through 2026 but remains unprofitable with increasing losses over the past five years. While Alector's management and board are experienced, the stock exhibits high volatility and significant insider selling was reported recently. Continued focus on progranulin-elevating programs may offer potential future value amidst these uncertainties.
-
Jump into the full analysis health report here for a deeper understanding of Alector.
-
Examine Alector's earnings growth report to understand how analysts expect it to perform.
Clarus
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Clarus Corporation designs, develops, manufactures, and distributes outdoor equipment and lifestyle products both in the United States and internationally, with a market cap of approximately $176.85 million.